These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 21175545)

  • 1. Beraprost sodium, an orally active prostaglandin I(2) analog, improves renal anemia in hemodialysis patients with peripheral arterial disease.
    Moriya H; Ishioka K; Honda K; Oka M; Maesato K; Ikee R; Hidaka S; Ohtake T; Kobayashi S
    Ther Apher Dial; 2010 Oct; 14(5):472-6. PubMed ID: 21175545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oral beraprost sodium, a prostaglandin I2 analogue, on endothelium dependent vasodilatation in the forearm of patients with coronary artery disease.
    Ohata S; Ishibashi Y; Shimada T; Takahashi N; Sugamori T; Sakane T; Hirano Y; Oyake N; Murakami Y; Higami T
    Clin Exp Pharmacol Physiol; 2006 Apr; 33(4):381-7. PubMed ID: 16620305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients.
    Ohtake T; Sato M; Nakazawa R; Kondoh M; Miyaji T; Moriya H; Hidaka S; Kobayashi S
    Ther Apher Dial; 2014 Feb; 18(1):1-8. PubMed ID: 24499078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
    El-Khatib M; Duncan HJ; Kant KS
    Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 12-week clinical effects of erythropoietin espogen in end stage renal patients undergoing hemodialysis.
    Thitiarchakul S; Tasanarong A
    J Med Assoc Thai; 2007 Apr; 90(4):636-42. PubMed ID: 17487116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
    Zehnder C; Blumberg A
    Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
    Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
    J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of beraprost sodium, a stable prostacyclin analogue, on cardiac allograft vasculopathy in rats.
    Kurisu Y; Orihashi K; Sueda T; Kajihara H; Matsuura Y
    Hiroshima J Med Sci; 1997 Mar; 46(1):11-9. PubMed ID: 9114563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal anemia: comparing current Eastern and Western European management practice (ORAMA).
    Wiecek A; Covic A; Locatelli F; Macdougall IC;
    Ren Fail; 2008; 30(3):267-76. PubMed ID: 18350446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of anemia and hyperhomocysteinemia on mortality of patients on hemodialysis.
    Anees M; Mumtaz A; Ibrahim M; Shaheen SM; Asghar A
    Iran J Kidney Dis; 2010 Jan; 4(1):60-5. PubMed ID: 20081306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
    Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
    Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of oral L-carnitine therapy in chronic hemodialysis patients.
    Sabry AA
    Saudi J Kidney Dis Transpl; 2010 May; 21(3):454-9. PubMed ID: 20427868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
    Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
    Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis.
    Goh BL; Ong LM; Sivanandam S; Lim TO; Morad Z;
    Nephrology (Carlton); 2007 Oct; 12(5):431-6. PubMed ID: 17803464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.